GlassScriptPhysician profile
Jawad Qureshi
NPI 1811926769
$4,380.39
in general payments reported to CMS, 2019-2025
25 companies · $910 in 2025
The $910 reported for 2025 was more than what 75% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $556 · 2021: $1,903 · 2022: $201 · 2023: $185 · 2024: $626 · 2025: $910.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,720.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,720.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $1,649.89 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $762.09 | 2019-2025 | Eylea Hd, Eylea |
| Apellis Pharmaceuticals, INC. | $333.90 | 2022-2025 | Syfovre |
| Medtronic Vascular, INC. | $256.12 | 2019 | |
| Abbvie INC. | $215.06 | 2022-2025 | |
| Genentech USA, INC. | $209.19 | 2023-2025 | Vabysmo |
| Astellas Pharma US INC | $201.83 | 2024-2025 | Izervay |
| Abbott Laboratories | $145.48 | 2021 | |
| Allergan, INC. | $119.23 | 2019 | |
| Kala Pharmaceuticals, INC. | $109.72 | 2019 | |
| Genentech, INC. | $108.01 | 2021 | |
| Sandoz INC. | $72.01 | 2024-2025 | Cimerli |
| Biotissue Holdings INC. | $46.44 | 2022 | |
| Novartis Pharmaceuticals Corporation | $38.60 | 2019 | |
| Alimera Sciences, INC. | $27.82 | 2024 | Yutiq, Iluvien |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coherus Oncology, INC. | $27.01 | 2024 | |
| Eyepoint US, INC. | $24.06 | 2022 | |
| Notal Vision, INC. | $17.16 | 2019 | |
| Bausch & Lomb Americas INC. | $16.77 | 2022 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jawad Qureshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.